Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy

Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospecti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Endocrinol (Lausanne)
Hlavní autoři: Grisanti, Salvatore, Cosentini, Deborah, Laganà, Marta, Morandi, Alessandra, Lazzari, Barbara, Ferrari, Laura, Volta, Alberto Dalla, Ambrosini, Roberta, Ferrari, Vittorio Domenico, Sigala, Sandra, Berruti, Alfredo
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Endocrinology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7943871/
https://ncbi.nlm.nih.gov/pubmed/33716976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.624102
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky